Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3209590 in healthy participants and type 2 diabetes
NCT02942914Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Dec 2016; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02942914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942914.